Search Results - "Vaylet, F."

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program by Leduc, C., Merlio, J.P., Besse, B., Blons, H., Debieuvre, D., Bringuier, P.P., Monnet, I., Rouquette, I., Fraboulet-Moreau, S., Lemoine, A., Pouessel, D., Mosser, J., Vaylet, F., Langlais, A., Missy, P., Morin, F., Moro-Sibilot, D., Cadranel, J., Barlesi, F., Beau-Faller, M.

“…EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR-mutated…”
Get full text

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) by Gervais, R., Ducolone, A., Breton, J.-L., Braun, D., Lebeau, B., Vaylet, F., Debieuvre, D., Pujol, J.-L., Tredaniel, J., Clouet, P., Quoix, E.

“…Background: Taxotere® (docetaxel) at the dose of 75 mg/m2 every 3 weeks is a standard therapy for pretreated non-small-cell lung cancer (NSCLC). The aim of…”
Get full text

Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma by Hofman, P., Ilie, M., Hofman, V., Roux, S., Valent, A., Bernheim, A., Alifano, M., Leroy-Ladurie, F., Vaylet, F., Rouquette, I., Validire, P., Beau-Faller, M., Lacroix, L., Soria, J.C., Fouret, P.

“…Immunohistochemistry has been proposed as a specific and sensitive method to identify EGFR mutations or ALK rearrangements in lung tumours. We assessed EGFR…”
Get full text

Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases by Bernard, C, Maucort-Boulch, D, Varron, L, Charlier, C, Sitbon, K, Freymond, N, Bouhour, D, Hot, A, Masquelet, A C, Valeyre, D, Costedoat-Chalumeau, N, Etienne, M, Gueit, I, Jouneau, S, Delaval, P, Mouthon, L, Pouget, J, Serratrice, J, Brion, J-P, Vaylet, F, Bremont, C, Chennebault, J M, Jaffuel, S, Broussolle, C, Lortholary, O, Sève, P

“…To describe the main characteristics and the treatment of cryptococcosis in patients with sarcoidosis. Multicenter study including all patients notified at the…”
Get full text

Pulmonary nocardiosis in immunocompetent patients: can COPD be the only risk factor? by Rivière, F, Billhot, M, Soler, C, Vaylet, F, Margery, J

Get full text

Mycobacterial pulmonary infection due to Mycobacterium simiae by Gaspard, W, N'Gampolo, I, Rivière, F, Lefloch, H, Margery, J, Marotel, C, Soler, C, Vaylet, F

“…Mycobacterium simiae pulmonary infections remain exceptional in France. We report a case of M. simiae lung infection and a 10-year follow-up in a…”
Get more information

Polymyalgia rheumatica revealing a lung cancer by Cocquempot, K, Defuentes, G, Duron-Martineau, S, Berets, O, Vaylet, F, Margery, J

“…Polymyalgia rheumatica is an inflammatory condition belonging to the connective tissue diseases, which occurs quite frequently in the elderly. Previously,…”
Get more information

A rare pulmonary tumour, primary malignant melanoma by Saint-Blancard, P, Vaylet, F, Jancovici, R

“…Malignant melanoma most commonly presents as a primary neoplasm of the skin, but has been described in other mucosal sites. Rarely, malignant melanomas have…”
Get more information

Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer by Quoix, E., Lebeau, B., Depierre, A., Ducolone, A., Moro-Sibilot, D., Milleron, B., Breton, J. L., Lemarie, E., Pujol, J. L., Brechot, J. M., Zalcman, G., Debieuvre, D., Vaylet, F., Vergnenegre, A., Clouet, P.

“…Background: The survival benefit associated with first-line chemotherapy in advanced lung cancer led to the need for second-line chemotherapy. Docetaxel…”
Get full text

A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC) by Tredaniel, J, Mornex, F, Barillot, I, Diaz, O, Hennequin, C, Le Pechoux, C, Lavole, A, Giraud, P, Souquet, P-J, Teixeira, L, Vaylet, F, Zalcman, G, Baudrin, L, Morin, F, Milleron, B

“…Cisplatin-based chemotherapy and concurrent radiotherapy are the standard treatments for locally advanced unresectable NSCLC. New therapeutic combinations…”
Get more information

Randomized phase II trial of first-line gefitinib, gemcitabine or docetaxel in performance status (PS) 2 or 3 non-small cell lung cancer (NSCLC) patients (IFCT-0301): elderly patients analysis by Des Guetz, G, Westeel, V, Morin, F, Baudrin, L, Gounant, V, Lebeau, B, Vaylet, F, Urban, T, Barlesi, F, Moro-Sibilot, D, Souquet, P.J, Debieuvre, D, Braun, D, Fraboulet, G, Chouahnia, K, Morere, J.F

Get full text

PET-CT for evaluation of the solitary pulmonary nodule: an update by Groheux, D, Hindié, E, Trédaniel, J, Giraudet, A-L, Vaylet, F, Berenger, N, Moretti, J-L

“…Positron emission tomography (PET) with 18F-FDG has become an important tool for the characterization of solitary pulmonary nodules (SPN). The results of the…”
Get more information

Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000) by Depierre, A, Lagrange, J L, Theobald, S, Astoul, P, Baldeyrou, P, Bardet, E, Bazelly, B, Bréchot, J M, Breton, J L, Douillard, J Y, Grivaux, M, Jacoulet, P, Khalil, A, Lemarié, E, Martinet, Y, Massard, G, Milleron, B, Molina, T, Moro-Sibilot, D, Paesmans, M, Pujol, J L, Quoix, E, Ranfaing, E, Rivière, A, Sancho-Garnier, H, Souquet, P J, Spaeth, D, Stoebner-Delbarre, A, Thiberville, L, Touboul, E, Vaylet, F, Vergnon, J M, Westeel, V

Get full text

Pulmonary malignant melanoma: primary or metastatic? by Rivière, F, Bonnichon-Py, A, Le Floch, H, Salles, Y, Staub, E, Mairovitz, A, Foehrenbach, H, Margery, J, Pons, F, Marotel, C, Vaylet, F

“…Primary pulmonary malignant melanoma is rare (0.01% of pulmonary cancers); only 25 cases are published in the literature. The diagnosis of primary pulmonary…”
Get more information

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial by Peters, S., Dafni, U., Dómine, M., Popat, S., Andrade, J., Becker, A., Moro-Sibilot, D., Curioni-Fontecedro, A., Molinier, O., Nackaerts, K., Insa Mollá, A., López Vivanco, G., Madelaine, J., Faehling, M., Griesinger, F., González Larriba, J.L., Provencio Pulla, M., Vervita, K., Roschitzki-Voser, H., Ruepp, B., Mitchell, P., Le Pechoux, C., De Ruysscher, D., Stahel, R., Hiltbrunner, A., Gasca-Ruchti, A., Giacomelli, N., Kammler, R., Marti, N., Pfister, R., Piguet, A.C., Roux, S., Troesch, S., Schweri, R., Zigomo, I., Tsourti, Z., Tsouprou, S., Kassapian, M., Vervita, K., Dimopoulou, G., Andriakopoulou, C., Morin, F., Amour, E., Mariaule, G., Archirel, N., Fernandez, M., Pereira, E., Benito, L., Lopez, K., Hernández, A., Chinchen, S., Jurkovic, H., Livingstone, A., Walker, M., Mitchell, P., Ng, S., Steer, C., Briscoe, K., Saqib, A., O’Byrne, K., Chittajallu, B.R., Hughes, B.G., Black, A., Nackaerts, K., Werner, H., Gervais, R., Zalcman, G., Monnet, I., Moro-Sibilot, D., Molinier, O., Girard, N., Souquet, P.-J., Barlesi, F., Debieuvre, D., Senellart, H., Poudenx, M., Dixmier, A., Pouessel, D., Cadranel, J., Lena, H., Quoix, E., Friard, S., Audigier-Valette, C., Mazieres, J., Pichon, E., Faehling, M., Kokowski, K., Griesinger, F., Tufman, A., de Langen, J., González Larriba, J.L., Insa, A., Massutí, B., Pulla, M.P., Aix, S.P., Villanueva, N., Andrade, J., Curioni-Fontecedro, A., Franks, K., Califano, R.

“…Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell…”
Get full text

A case of atypical pericarditis by Le Floch, H, Niang, A, Rivière, F, Bonnichon-Py, A, Mairovitz, A, Staub, E, Saint-Blancard, P, Margery, J, Marotel, C, Vaylet, F

“…An acute viral pericarditis may reveal a congenital pericardial abnormality. We report the case of a young man of 29 years in whom the development of rapidly…”
Get more information

Positron emission tomography in the diagnosis and follow up of non-small cell lung cancer by Vaylet, F, Rivière, F, Le Floch, H, Bonnichon, A, Mairovitz, A, Staub, E, Bonardel, G, Margery, J, Mantzarides, M, Marotel, C, Foehrenbach, H

“…In the space of a few years 18F-FDG PET scanning has acquired a place in the management of all stages of the clinical care of patients with lung cancer. Its…”
Get more information

Lung cancer in the elderly subject by Albrand, G, Biron, E, Boucot, I, Couderc, L J, Crestani, B, Dombret, M C, Guenard, H, Grivaux, M, Hervy, M P, Housset, B, Jougon, J, Orvoen-Frija, E, Piette, F, Pignon, T, Pinganaud, G, Puisieux, F, Quoix, E, Sauty, E, Vaylet, F, Wary, B, Weill-Engerer, S, Westeel, V, Wislez, M

“…In France, the average age for the diagnosis of bronchial carcinoma is 64. It is 76 in the population of over 70. In fact, its incidence increases with age…”
Get more information

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial by Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., Le Caer, H., Moro-Sibilot, D., Fournel, P., Oster, J.P., Chatellain, P., Barre, P., Jeannin, G., Mourlanette, P., Derollez, M., Herman, D., Renault, A., Dayen, C., Lamy, P.J., Langlais, A., Morin, F., Zalcman, G., Westeel, V., Poudenx, M., Mazieres, J., Martinet, Y., Gury, J-P., Baize, N., Dumont, P., Vaylet, F., Foucher, P., Dauba, J., Tredaniel, J., Laize, H., Petit, L., Coëtmeur, D., Doubre, H., Pichon, E., Schneider, S., Goutorbe, F., Gervais, R., Zaegel, M., Dehette, S., Coudert, B., Duhamel, J-P., Dixmier, A., Thiberville, L., Deguiral, P., Monnot, H., Romand, P., Berard, H., Raspaud, C.

“…IFCT study administering 7.5 mg/kg Bevacizumab plus chemotherapy after chemotherapy induction did not improve outcomes in extensive SCLC patients. This…”
Get full text

Bronchogenic carcinoma in patients with pulmonary histiocytosis X by Sadoun, D, Vaylet, F, Valeyre, D, Natali, F, Georges, R, Allard, P, Battesti, J P

“…Five cases of bronchogenic carcinoma were observed among 93 patients with pulmonary histiocytosis X (Hx). Mean age at the time of diagnosis of Hx was 42 years;…”
Get more information